RadNet (RDNT)
(Delayed Data from NSDQ)
$68.58 USD
+3.59 (5.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $68.61 +0.03 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.58 USD
+3.59 (5.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $68.61 +0.03 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum B VGM
Zacks News
3 Reasons Growth Investors Will Love RadNet (RDNT)
by Zacks Equity Research
RadNet (RDNT) possesses solid growth attributes, which could help it handily outperform the market.
Amwell Shares Rise After Expansion of Portfolio With Hello Heart
by Zacks Equity Research
AMWL adds Hello Heart to its clinical programs, offering heart health solutions to members with high blood pressure or cholesterol via its Converge platform.
DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?
by Zacks Equity Research
DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.
RadNet (RDNT) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for RadNet (RDNT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
RadNet (RDNT) Q2 Earnings Match Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 0% and 5.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Astrana Health, Inc. (ASTH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of 5.26% and 9.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ATI Physical Therapy, Inc. (ATIP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy (ATIP) delivered earnings and revenue surprises of 7.60% and 0.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate RadNet (RDNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?
by Zacks Equity Research
RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.73% and 0.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
Zacks.com featured highlights include G-III Apparel, RadNet and Hess
by Zacks Equity Research
G-III Apparel, RadNet and Hess are part of the Zacks Screen of the Week article.
Buy These 3 Momentum Stocks Backed by the Driehaus Strategy
by Tirthankar Chakraborty
G-III Apparel Group (GIII), RadNet (RDNT) and Hess (HES) have been selected as the momentum picks for the day using the Driehaus strategy.
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
by Shaun Pruitt
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
The Zacks Analyst Blog Highlights CareCloud, DaVita, RadNet, SkyWest and American Express
by Zacks Equity Research
CareCloud, DaVita, RadNet, SkyWest and American Express are included in this Analyst Blog.
New Strong Buy Stocks for June 12th
by Zacks Equity Research
RDNT, ESLT, CLS, LNTH and ASBFY have been added to the Zacks Rank #1 (Strong Buy) List on June 12, 2024.
5 Stocks to Gain as Service Side of the Economy Bounces Back
by Tirthankar Chakraborty
With service sector activity rebounding in recent times, it's worth placing bets on stocks such as CareCloud (CCLD), DaVita (DVA), RadNet (RDNT), SkyWest (SKYW) and American Express (AXP).
RadNet, Inc. (RDNT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
RadNet (RDNT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Why Growth Investors Shouldn't Overlook RadNet (RDNT)
by Zacks Equity Research
RadNet (RDNT) could produce exceptional returns because of its solid growth attributes.
All You Need to Know About RadNet (RDNT) Rating Upgrade to Strong Buy
by Zacks Equity Research
RadNet (RDNT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RadNet (RDNT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 177.78% and 2.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
RadNet (RDNT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
RadNet (RDNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will RadNet (RDNT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
RadNet (RDNT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RadNet (RDNT) Is Up 14.75% in One Week: What You Should Know
by Zacks Equity Research
Does RadNet (RDNT) have what it takes to be a top stock pick for momentum investors? Let's find out.